Therefore, we reasoned that blocking the Glu‐GSH flux using a GCLC inhibitor would increase the antigen presentation in tumor cells and enhance the efficacy of ICB therapy in treating CRC. The gene discussed is GCLC; the disease is colorectal carcinoma.